Post-Market Clinical Follow-up Study of the REDAPT Monolithic Sleeveless Stem and Acetabular Components Devices Used for Hip Replacement Surgery.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03610789|
Recruitment Status : Enrolling by invitation
First Posted : August 1, 2018
Last Update Posted : November 26, 2019
|Condition or disease||Intervention/treatment|
|Hip Replacement||Device: REDAPT|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Multicenter, Post-Market Clinical Follow-up Study of Subjects With REDAPT Revision Monolithic Sleeveless Stem and/or Acetabular Components Previously Implanted|
|Actual Study Start Date :||May 7, 2018|
|Estimated Primary Completion Date :||August 1, 2028|
|Estimated Study Completion Date :||December 1, 2028|
REDAPT Revision Femoral System
REDAPT Revision Femoral System Monolithic Sleeveless Stems and/or Acetabular Components
REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
- Revision rate [ Time Frame: 10 years post-op ]Monolithic sleeveless stem and acetabular components cumulative revision rate
- EuroQul Five Dimensions Questionnaire EQ-5D-5L [ Time Frame: Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively ]Clinical evaluation to assess changes over time from pre-op through 10 years post-op. The EuroQol Five Dimensions (EQ-5D) Questionnaire is an instrument that derives a single index for Quality of Life (QoL) and has two sections. The first section consists of five questions covering the dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The second part consists of a 20-centimeter vertical VAS ranging from 0 to 100. It records the respondent's self-rated health where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. EQ-5D-5L is completed by the subject.
- Functional outcomes as determined by the Hip Disability Osteoarthritis Outcome (HOOS) score [ Time Frame: Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively ]HOOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and hip related QOL. The last week is taken into consideration when answering the questions. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
- Radiographic assessments [ Time Frame: Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively ]Loosening as indicated by radiolucencies (RLL) > 2mm; Lack of evidence of surface wear or particulate debris generation as indicated by early osteolysis, implant migration, or other clinical or radiographic abnormalities.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03610789
|United States, California|
|Eisenhower Medical Center-Hospital|
|Rancho Mirage, California, United States, 92270|
|San Diego, California, United States, 92103|
|United States, New York|
|New York University Hospital for Joint Disease|
|New York, New York, United States, 10003|
|Hospital for Surgery- New York|
|New York, New York, United States, 10021|
|United States, Texas|
|Houston Methodist Hospital Department of Orthopedic Surgery|
|Houston, Texas, United States, 77030|
|Study Chair:||Tracey Brengola||Smith & Nephew, Inc.|